For pharmaceutical manufacturers, sponsors, and life sciences organizations operating in the Australian market, ensuring the ongoing safety of therapeutic goods is not just a best practice—it is a mandatory obligation. The moment a medicine is approved and listed on the Australian Register of Therapeutic Goods (ARTG), the post-market safety surveillance begins, overseen by the demanding but crucial regulatory body: the Therapeutic Goods Administration (TGA).

While clinical trials provide foundational safety data, they rarely capture the full spectrum of potential adverse drug reactions (ADRs), especially rare events that only emerge after widespread use. This is where a robust Pharmacovigilance (PV) system becomes your most critical operational asset.

The TGA's Mandate: What Sponsors Must Know

The TGA's pharmacovigilance framework is clear: sponsors of both registered and listed medicines must continuously collect, evaluate, and act upon safety information.

Key obligations for sponsors include:

Mandatory Reporting: Timely reporting of all suspected Adverse Drug Reactions (ADRs). The TGA gives particular scrutiny to serious or unexpected events, those related to newly registered products, or those involving death or hospitalization.

Compliance with GVP: Adhering to Australia's Good Pharmacovigilance Practices (GVP).

Risk Management: Implementing and maintaining effective Risk Management Plans (RMPs).

Compliance with these stringent, evolving guidelines requires dedicated expertise, resources, and a system capable of managing safety data efficiently on a global and local scale.

Why Outsource Your Australian Pharmacovigilance to DDReg Pharma?

Faced with the complexities of establishing a local PV system—including securing a qualified Australian PV Contact Person—many organizations are choosing to partner with a specialized, PV outsourced service provider in Australia.

DDReg Pharma offers an ideal solution: a partnership that merges global PV expertise with deep, localized regulatory knowledge of the Australian landscape.

Our Value Proposition:

End-to-End TGA Compliance: We ensure full adherence to TGA guidelines and Australia GVP, protecting your market authorization status.

Local Expertise, Global Standards: Our blend of international best practices (E2B(R3) compliance, MedDRA, WHO Drug Dictionary) and specific local TGA requirements ensures a seamless and audit-ready operation.

The Australian Pharmacovigilance Contact Person (QPPV): We provide retainer services for the Qualified Person for Pharmacovigilance (QPPV Services) or Deputy QPPV roles, fulfilling this critical local requirement without the need to hire and train a permanent internal resource.

Our Comprehensive Suite of PV Services in Australia

DDReg Pharma provides tailored drug safety solutions designed to streamline your operations, reduce risk, and accelerate market access.

Core PV Service    How DDReg Ensures TGA Compliance
ICSR Processing & Submission    Triage and processing of Individual Case Safety Reports (ICSRs) and SUSARs through E2B(R3) compliant databases, including quality check, medical review, and submission within TGA-mandated timelines.
Risk Management Plan (RMP)    Drafting, reviewing, and maintaining comprehensive RMPs. This includes preparing customized risk classification procedures, assessing potential risks, and supporting the implementation of supplementary measures like Post-Authorization Safety Studies (PASS).
Aggregate Reports    Preparation of all mandatory periodic reports, including PBRERs (Periodic Benefit-Risk Evaluation Reports), PSURs (Periodic Safety Update Reports), and DSURs (Development Safety Update Reports).
Signal Management    Proactive identification of new safety signals or changes in risk using in-house tools, ICSR databases, literature monitoring, and regulatory agency website monitoring, culminating in recommendations for risk minimization and label updates.
PV Quality Management System    Oversight, gap assessments, and mock audits to prepare for competent authority inspections, ensuring your PV system is robust, compliant, and ready for TGA scrutiny.
Blog Content: Navigating Australia's TGA Pharmacovigilance Requirements: Why Compliance Demands an Expert Partner
?? Ensuring Drug Safety Down Under: The Critical Role of Pharmacovigilance in Australia

For pharmaceutical manufacturers, sponsors, and life sciences organizations operating in the Australian market, ensuring the ongoing safety of therapeutic goods is not just a best practice—it is a mandatory obligation. The moment a medicine is approved and listed on the Australian Register of Therapeutic Goods (ARTG), the post-market safety surveillance begins, overseen by the demanding but crucial regulatory body: the Therapeutic Goods Administration (TGA).

While clinical trials provide foundational safety data, they rarely capture the full spectrum of potential adverse drug reactions (ADRs), especially rare events that only emerge after widespread use. This is where a robust Pharmacovigilance (PV) system becomes your most critical operational asset.

The TGA's Mandate: What Sponsors Must Know

The TGA's pharmacovigilance framework is clear: sponsors of both registered and listed medicines must continuously collect, evaluate, and act upon safety information.

Key obligations for sponsors include:

Mandatory Reporting: Timely reporting of all suspected Adverse Drug Reactions (ADRs). The TGA gives particular scrutiny to serious or unexpected events, those related to newly registered products, or those involving death or hospitalization.

Compliance with GVP: Adhering to Australia's Good Pharmacovigilance Practices (GVP).

Risk Management Services: Implementing and maintaining effective Risk Management Plans (RMPs).

Compliance with these stringent, evolving guidelines requires dedicated expertise, resources, and a system capable of managing safety data efficiently on a global and local scale.

Why Outsource Your Australian Pharmacovigilance to DDReg Pharma?

Faced with the complexities of establishing a local PV Services—including securing a qualified Australian PV Contact Person—many organizations are choosing to partner with a specialized, outsourced service provider.

DDReg Pharma offers an ideal solution: a partnership that merges global PV expertise with deep, localized regulatory knowledge of the Australian landscape.

Our Value Proposition:

End-to-End TGA Compliance: We ensure full adherence to TGA guidelines and Australia GVP, protecting your market authorization status.

Local Expertise, Global Standards: Our blend of international best practices (E2B(R3) compliance, MedDRA, WHO Drug Dictionary) and specific local TGA requirements ensures a seamless and audit-ready operation.

The Australian Pharmacovigilance Contact Person (QPPV): We provide retainer services for the Qualified Person for Pharmacovigilance (QPPV) or Deputy QPPV roles, fulfilling this critical local requirement without the need to hire and train a permanent internal resource.

Our Comprehensive Suite of PV Services in Australia

DDReg Pharma provides tailored drug safety solutions designed to streamline your operations, reduce risk, and accelerate market access.

Core PV Service    How DDReg Ensures TGA Compliance
ICSR Processing & Submission    Triage and processing of Individual Case Safety Reports (ICSRs) and SUSARs through E2B(R3) compliant databases, including quality check, medical review, and submission within TGA-mandated timelines.
Risk Management Plan (RMP)    Drafting, reviewing, and maintaining comprehensive RMPs. This includes preparing customized risk classification procedures, assessing potential risks, and supporting the implementation of supplementary measures like Post-Authorization Safety Studies (PASS).
Aggregate Reports    Preparation of all mandatory periodic reports, including PBRERs (Periodic Benefit-Risk Evaluation Reports), PSURs (Periodic Safety Update Reports), and DSURs (Development Safety Update Reports).
Signal Management    Proactive identification of new safety signals or changes in risk using in-house tools, ICSR databases, literature monitoring, and regulatory agency website monitoring, culminating in recommendations for risk minimization and label updates.
PV Quality Management System    Oversight, gap assessments, and mock audits to prepare for competent authority inspections, ensuring your PV system is robust, compliant, and ready for TGA scrutiny.
Partner for Success

In the demanding environment of Australian pharmacovigilance, the right partner shapes everything—from signal detection and RMP creation to timely safety reporting and successful market access.

DDReg Pharma is your trusted choice for pharmacovigilance consulting services in Australia. By partnering with us, you gain a dedicated team of experienced risk management specialists and QPPVs, ensuring continuous compliance and, most importantly, enhanced patient safety.

Ready to achieve seamless TGA pharmacovigilance compliance?

Connect with Our Experts today to learn how DDReg can manage your end-to-end drug safety needs in Australia.